JOMPAC

Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

EndNote Style
Index
Original Article
The predictive role of systemic immune-inflammation index in non-ischemic cardiomyopathy
Aims: The systemic immune-inflammation index (SII), a useful marker of systemic inflammation, has been shown to be associated with cardiovascular diseases in previous studies. Inflammation is known to have a significant role in heart failure, but no study has evaluated the relationship between inflammatory parameters and prognosis in patients with non-ischemic cardiomyopathy (NICM). This study aimed to explore the relationship between SII and long-term mortality in patients with non-ischemic cardiomyopathy.
Methods: The study enrolled 326 consecutive patients with NICM. The median 25-month follow-up mortality results of the patients were recorded retrospectively. SII, a combined index based on the count of three parameters, was calculated as follows: neutrophil count x platelet count/lymphocyte count. Patients with a higher SII value than the median SII were accepted as having a high SII, and the remaining patients were defined as having a low SII. The survival curves of the patients with high and low SII values during the study period were analyzed using the Kaplan-Meier method.
Results: The mean age of the participants was 46.6 years. The mean SII value was 598.4 in patients without mortality and 722.7 in those with mortality. In the multivariate logistic regression analysis, SII was found to be an independent predictor of mortality. The median SII value of the patients who participated in the study was 644. Upon dividing the patients into two groups according to the median SII value, the mortality rate was determined to be 48.4% in the high SII group and 27.4% in the low SII group.
Conclusion: High SII values were observed to be associated with long-term mortality in patients with NICM. SII, which is easily accessed and simply calculated, can be used to predict mortality risk in these patients. Prospective and larger cohort studies are needed to clarify the causality of this relationship.


1. Hodler J, Kubik-Huch RA, von Schulthess GK, eds. Diseases ofthe chest, breast, heart and vessels 2019-2022: Diagnostic andInterventional Imaging. Springer: 2019.
2. Li X, Zhang X, Liu Y, et al. Relationship between serum chlorideand prognosis in non-ischaemic dilated cardiomyopathy: a largeretrospective cohort study. BMJ Open. 2022;12(12):e067061.
3. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy:the complexity of a diverse genetic architecture. Nat Rev Cardiol.2013;10(9):531-547.
4. Del Mestre E, Pio Loco Detto Gava C, Paldino A, et al. Arrhythmicrisk stratification in non-ischaemic dilated cardiomyopathy. EurHeart J Suppl. 2023;25(Supplement_B):B144-B148.
5. Weintraub RG, Semsarian C, Macdonald P. Dilatedcardiomyopathy. Lancet. 2017;390(10092):400-414.
6. Merlo M, Cannatà A, Gobbo M, Stolfo D, Elliott PM, Sinagra G.Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail.2018;20(2):228-239.
7. Sinagra G, Merlo M, Pinamonti B, eds. Dilated Cardiomyopathy:From Genetics to Clinical Management. Springer: 2019.
8. Zecchin M, Merlo M, Pivetta A, et al. How can optimization ofmedical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilatedcardiomyopathy presenting with “SCD-HeFT criteria?”. Am JCardiol. 2012;109(5):729-735.
9. Halliday BP, Gulati A, Ali A, et al. Sex- and age-based differencesin the natural history and outcome of dilated cardiomyopathy.Eur J Heart Fail. 2018;20(10):1392-1400.
10. Ferreira A, Ferreira V, Antunes MM, et al. Dilatedcardiomyopathy: a comprehensive approach to diagnosis and riskstratification. Biomedicines. 2023;11(3):834.
11. Simon T, Becker R, Voss F, et al. Elevated B-type natriuretic peptidelevels in patients with nonischemic cardiomyopathy predictoccurrence of arrhythmic events. Clin Res Cardiol. 2008;97(5):306-309.
12. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markersand onset of cardiovascular events: results from the health ABCstudy. Circulation. 2003;108(19):2317-2322.
13. Sampietro T, Neglia D, Bionda A, et al. Inflammatory markersand serum lipids in idiopathic dilated cardiomyopathy. Am JCardiol. 2005;96(12):1718-1720.
14. Kaneko K, Kanda T, Yamauchi Y, et al. C-Reactive protein indilated cardiomyopathy. Cardiol. 1999;91(4):215-219.
15. Wang BL, Tian L, Gao XH, et al. Dynamic change of the systemicimmune inflammation index predicts the prognosis of patientswith hepatocellular carcinoma after curative resection. Clin ChemLab Med. 2016;54(12):1963-1969.
16. Tang Y, Zeng X, Feng Y, et al. Association of systemic immune-inflammation index with short-term mortality of congestiveheart failure: a retrospective cohort study. Front Cardiovasc Med.2021;8:753133.
17. Öcal L, Keskin M, Cerşit S, et al. Systemic immune-inflammationindex predicts in-hospital and long-term outcomes in patientswith ST-segment elevation myocardial infarction. Coron ArteryDis. 2022;33(4):251-260.
18. Wang Y, Ni Q. Prognostic and clinicopathological significanceof systemic immune-inflammation index in cancer patientsreceiving immune checkpoint inhibitors: a meta-analysis. AnnMed. 2023;55(1):808-819.
19. Xie Y, Cen H, Wang L, et al. Relationships between inflammatoryparameters derived from complete blood count and quantitativeflow ratio in patients with stable coronary artery disease. Angiol.2023:00033197231197804. doi: 10.1177/00033197231197804
20. Wang X, Ni Q, Wang J, Wu S, Chen P, Xing D. Systemicinflammation response index is a promising prognostic markerin elderly patients with heart failure: a retrospective cohort study.Front Cardiovasc Med. 2022;9:871031.
21. Yuan M, Ren F, Gao D. The value of SII in predicting the mortalityof patients with heart failure. Dis Markers. 2022;2022:3455372.
22. Lin KB, Fan FH, Cai MQ, et al. Systemic immune inflammationindex and system inflammation response index are potentialbiomarkers of atrial fibrillation among the patients presentingwith ischemic stroke. Eur J Med Res. 2022;27(1):106.
23. Wu AH. Management of patients with non-ischaemiccardiomyopathy. Heart. 2007;93(3):403-408.
24. Zhang ZH, Meng FQ, Hou XF, et al. Clinical characteristicsand long-term prognosis of ischemic and non-ischemiccardiomyopathy. Indian Heart J. 2020;72(2):93-100.
25. Cho JH, Cho HJ, Lee HY, et al. Neutrophil-lymphocyte ratio inpatients with acute heart failure predicts in-hospital and long-term mortality. J Clin Med. 2020;9(2):557.
26. Reina-Couto M, Pereira-Terra P, Quelhas-Santos J, Silva-PereiraC, Albino-Teixeira A, Sousa T. Inflammation in human heartfailure: major mediators and therapeutic targets. Front Physiol.2021;12:746494.
27. Strand ME, Vanhaverbeke M, Henkens MTHM, et al.Inflammation and syndecan-4 shedding from cardiac cellsin ischemic and non-ischemic heart disease. Biomedicines.2023;11(4):1066.
28. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokineparameters and mortality in patients with chronic heart failure.Circulation. 2000;102(25):3060-3067.
29. Kearney MT, Fox KA, Lee AJ, et al. Predicting death due toprogressive heart failure in patients with mild-to-moderatechronic heart failure. J Am Coll Cardiol. 2002;40(10):1801-1808.
Volume 5, Issue 1, 2024
Page : 36-41
_Footer